What NAD+ is, and what we know so far

Quick answer

NAD+ is short for nicotinamide adenine dinucleotide. The research review listed below describes it as declining with age, which has driven interest in ways to raise it. But raising NAD-related measures is not the same as helping people live longer or stay healthier. Human studies of oral precursors show biological activity, while evidence for meaningful health benefits remains unclear. Results vary. For NAD+ injections, the review found no eligible outcomes trials for anti-aging or wellness uses.

Start with the name, not the promise

NAD+ often appears in wellness messages alongside terms such as longevity and healthy aging. Those labels describe goals, not proven results. The review discusses several approaches under the broad idea of raising NAD+, including lifestyle approaches, oral precursors, and injections. That shared umbrella can hide major differences. Before considering any claim, identify the actual substance, how it is given, and what the seller says it will do.

Two precursors named in the review are nicotinamide riboside, or NR, and nicotinamide mononucleotide, or NMN. Researchers studied these separately from NAD+ itself. Their names can make a product list hard to follow, so ask for the full ingredient name rather than relying on a category label. A study of an oral precursor does not automatically answer questions about an NAD+ injection or a different finished product.

What the human research actually found

The systematic review listed below included human and rodent intervention studies. In humans, oral NR and NMN consistently changed NAD-related measures in blood or cells. Researchers call this target engagement: the intervention affected a measure tied to its research target. That finding supports biological activity. It does not, by itself, show that a person will feel better, function better, avoid illness, or live longer. Results vary across health outcomes.

The review found mixed effects on measures related to function, metabolism, blood vessels, and other aspects of healthy aging. Some findings were limited to particular outcomes, and many showed no effect. Oral NR and NMN were generally well tolerated over the studied weeks to months. That observation has limits. It does not establish safety for every person, every product, or use beyond the periods researchers actually studied.

Why an age-related change is not a treatment plan

A measure that changes with age can be a useful research clue. It is not enough to establish that changing the measure back will improve health. This is the key gap in many NAD+ messages. A claim may begin with an accurate observation about aging and then jump to a treatment promise. Ask what human evidence connects the proposed intervention to the specific benefit being advertised.

The review reported encouraging findings in rodent models, although effects differed across models and outcomes. Animal work can support further research, but it cannot settle what will happen in people. Keep those findings in a separate mental folder from human evidence. If a product page blends animal results with human lab changes, ask which study directly supports its patient benefit claim. Results vary, and that connection may remain unproven.

What remains unknown about injections

Injections deserve their own evidence discussion. The review found no eligible trials evaluating clinical outcomes from intravenous or intramuscular NAD+ itself for anti-aging or wellness purposes. It identified an intravenous NAD+ pilot about how the substance moves through the body, but that study lacked eligible clinical outcomes. Information about what happens after administration is not the same as evidence that treatment improves health or extends life.

The review also included a nonrandomized study of intravenous NMN that mainly added short-term safety and biomarker information. NMN is not NAD+ itself, and a biomarker is not a longevity outcome. This distinction matters when a clinic presents several citations together. Ask the clinician to sort each study by substance, route, and outcome before discussing whether any findings apply to the proposed care. Results vary, and clinical effectiveness remains inconclusive.

Choose a next step that matches your concern

A useful first step is to name your concern without using a product name. You might want to discuss a change in daily function, a symptom, or uncertainty about aging claims. That creates room for an evaluation rather than a shopping decision. A clinician can review your history before deciding what kind of assessment is appropriate. A general wish for longevity does not, on its own, establish a need for NAD+.

Possible next steps include a conversation about the evidence, an assessment of symptoms, or an in-person visit when needed. These are different from deciding to use a product. Ask what question any proposed test would answer and how the result could change care. A test or device is not automatically a prescription medicine. You can also choose to wait while evidence develops rather than treat uncertainty as a reason to act.

Bring information that makes the visit useful

Bring a current list of medicines and supplements, relevant health history, and any test results you already have. If an advertisement prompted the visit, save the exact claim and ingredient list. Include whether the product is taken by mouth or given by injection. This lets the clinician compare the claim with the actual evidence instead of trying to interpret a broad phrase such as cellular wellness.

Describe your goal in terms you can recognize in daily life, while leaving room for medical evaluation. Ask what evidence supports that goal, what remains unknown, and whether the proposed approach has been studied in people with relevant health histories. Results vary. Also ask how follow-up would work, what would trigger a change in plan, and whom to contact if a concern arises after the visit.

Understand safety and the limits of online care

MedlinePlus warns that unproven health products may have hidden ingredients, contamination, or harmful interactions. These warnings do not establish that every NAD-related product has those problems. They do explain why an ingredient list and product source matter. Discuss an unfamiliar product with a health care professional, especially if you take prescription medicines. Avoid treating words such as natural, advanced, or breakthrough as evidence of safety or effectiveness.

Verra Health provides US telehealth, where licensed clinicians review health history before making decisions. A prescription is never guaranteed. An online conversation cannot provide a hands-on examination, and a clinician may recommend in-person assessment. Ask what can be addressed remotely and what cannot. If a compounded medicine is discussed, understand that it is not FDA-approved. For emergency symptoms, call 911 rather than waiting for an online reply.

Leave with a decision framework, not a promise

Before agreeing to a next step, ask for a plain-language summary of the evidence, uncertainties, safety concerns, and alternatives. Include the option of no product. If cost is part of the decision, clarify visit and follow-up charges without assuming a prescription will result. Verra Health visit fees are non-refundable and are credited toward a first order within 30 days. That policy is separate from the clinical decision.

A balanced takeaway is that NAD-related research shows biological activity, but anti-aging and wellness effectiveness remains inconclusive. Results vary, and stronger research needs meaningful outcomes and longer follow-up. You do not need to choose between enthusiasm and dismissal. You can remain interested while asking for clear evidence. The most useful visit leaves you knowing what is supported, what is uncertain, and what practical next step fits your concern.